Clinical Trial Update: Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 update reporting safety and efficacy of Atiprimod in patients with low to intermediate-grade neuroendocrine carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma

Drugs mentioned

• Atiprimod

Snippet

Sponsor: Callisto Pharmaceuticals | Conditions: Neuroendocrine Carcinoma | Phase 2 | Status: COMPLETED